IPM works with cutting-edge ARV compounds as a result of our partnerships with pharmaceutical companies. Through royalty-free licensing agreements for eight ARVs or active pharmaceutical ingredients and exclusive worldwide rights for one ARV called dapivirine, we have access to an array of drugs with a variety of mechanisms of action against HIV infection.
The table below provides information on how IPM compounds work and their stage of development at IPM. Our clinical trials page lists IPM clinical trials that are currently under way.
|Compound||License||Mechanism of action||IPM development stage|
|Dapivirine||Janssen Sciences Ireland UC (previously Tibotec)||NNRTI: Reverse transcription|
|DS003 (BMS793)||BMS||gp120: Cell attachment|
|Darunavir||Janssen Sciences Ireland UC||Protease inhibitor: Protein synthesis and assembly|
|Maraviroc||ViiV Healthcare||CCR5: Cell Attachment|
|Tenofovir||Gilead||NRTI: Reverse transcription|
|DS001 (L167), DS004 (L872), DS005 (L882)||Merck||CCR5: Cell Attachment|
|DS007 (L-644 peptide)||Merck||gp41: Cell fusion|
* Trial product provided by IPM
** Compound is in different stages of development by other organizations
IPM’s active compounds target different steps in viral replication
The candidate microbicides in IPM’s product pipeline target four different steps in the viral replication cycle: attachment, fusion, reverse transcription, and protein synthesis and assembly.
- Cell attachment: Preventing the virus from attaching to human cells
- Cell fusion: Preventing the virus from entering human cells
- Reverse transcription: Preventing the virus from reproducing inside human cells
- Protein synthesis and assembly: Preventing the virus from producing new virus that can infect healthy cells
Learn more about how microbicides work.